好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Ipsilateral Silent Period Study in Relapsing Remitting Multiple Sclerosis during and after Motor Relapse
Clinical Neurophysiology
IN11 - (-)
003
Several studies showed abnormal iSP measures in MS, but data about iSP during and after a motor relapse are not available.
We compared 13 RRMS patients without disability who presented a first upper limb weakness with 19 healthy volunteers. Patients underwent clinical (MRC, NHPT) and neurophysiological examination (MEP latency, iSP onset, amount and duration) at study entry (T1 about one wk after the relapse) and end of the 16th week after a single attack involving for the first time upper arm motor function, unilaterally. iSP measures were obtained from the abductor pollicis brevis of the two sides.
MRC and time to complete NHPT in the affected (AA) were worse vs the unaffected (UA) arm and vs controls (p<0.05) at T1 but not at T2, being both measures significantly improved in AA at T2 vs T1 (p<0.05). MS vs controls: delayed iSP onset (AA,UA at T1,T2) p<0.05, lower iSP amount (AA, UA at T1,T2) without significant interhemispheric differences, duration iSP (UA at T1). In MS pts, MEPs had increased latency and lower amplitude in AA and UA vs controls at both times, in AA vs UA at both times, and in the AA at T1 vs AA T2 (p<0.05). At T1, iSP duration in UA inversely correlated with improvement of AA NHPT in T2 (r=-0.54, p=0.05) and not in T1. No correlation with NHPT/MRC of iSP duration in AA and MEPs latency/amplitude in either side.
Shortly after a relapse, transient increase of iSP duration over the unaffected limb would indicate impaired efficiency of the affected hemisphere to inhibit the unaffected. This impairment is transient and is related with future recovery outcome.
Authors/Disclosures
Arturo Nuara
PRESENTER 		No disclosure on file
No disclosure on file
Raffaella Chieffo, MD No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Peter A. Calabresi, MD, FAAN (Johns Hopkins University) Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Myelin Repair Foundation. The institution of Dr. Calabresi has received research support from Genentech. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Grant reveiwer with Myelin Repair Foundation. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Academic CME.
No disclosure on file
No disclosure on file
Giancarlo Comi, MD (University Vita-Salute) Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Letizia M. Leocani, MD (University Vita-Salute San Raffaele, INSPE) Dr. Leocani has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche . Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Med-ex learning.